Skip to main content
Year archive

Oxurion NV — 2019 filings

All 36 regulatory filings released by Oxurion NV (OXUR) in 2019, sourced directly from the official regulator.

36 Filings
2019 Period
2019 filings (36)
Filing Released Lang
Oxurion NV to Focus Clinical Development on Molecules Targeting VEGF Independent Pathways for Treatment of DME
Regulatory Filings
2019-12-20 English
OXUR Proxy 2ndEGM Dec2019 EN.pdf
Proxy Solicitation & Information Statement
2019-12-13 English
OXUR Proxy 2ndEGM Dec2019 NL.pdf
AGM Information
2019-12-13 Dutch
OXUR ConveningNotice 2ndEGM Dec2019 EN.pdf
Proxy Solicitation & Information Statement
2019-12-13 English
OXUR ConveningNotice 2ndEGM Dec2019 NL.pdf
AGM Information
2019-12-13 Dutch
OXUR Proxy EGM Dec2019 (NL English).pdf
AGM Information
2019-11-14 English
OXUR EGM Dec2019 SpecialBoardReport (NL English).pdf
Capital/Financing Update
2019-11-14 English
OXUR EGM Dec2019 ShareholdersRights (NL English).pdf
AGM Information
2019-11-14 English
OXUR Convening Notice EGM Dec2019 (ENG).pdf
AGM Information
2019-11-14 English
OXUR Convening Notice EGM Dec2019 (NL).pdf
AGM Information
2019-11-14 Dutch
OXUR BUQ3 181019 FIN.pdf
Earnings Release 9M 2019
2019-10-18 English
Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a novel, potent plasma kallikrein inhibitor for DME
Earnings Release Q3 2019
2019-09-09 English
TG GLOBAL - Financial report 30-06-2019 (EN) - final.pdf
Interim / Quarterly Report H1 2019
2019-09-05 English
TG GLOBAL - Financial report 30-06-2019 (NL) - final.pdf
Interim / Quarterly Report H1 2019
2019-09-05 Dutch
OXUR-BU H1 2019 PR - EN FIN.pdf
Interim / Quarterly Report H1 2019
2019-09-05 English
OXUR-BU H1 2019 FIN NL.pdf
Earnings Release H1 2019
2019-09-05 Dutch
Oxurion NV Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 (anti-PLGF), in Combination with Ranibizumab, for DME
Earnings Release Q3 2019
2019-08-21 English
OXUR transparency statement CLAY 100519 EN.pdf
Major Shareholding Notification
2019-05-10 English
OXUR transparency statement CLAY 100519 NL.pdf
Declaration of Voting Results & Voting Rights Announcements
2019-05-10 Dutch
OXUR AGM07May2019 Proxies.pdf
Proxy Solicitation & Information Statement
2019-05-10 Dutch
OXUR AGM07May2019 AttendanceList.pdf
AGM Information
2019-05-10 Dutch
OXUR AGM07May2019 MeetingMinutes.PDF
AGM Information
2019-05-10 English
OXUR transparency statement OXUR shares outstanding 100519 EN.pdf
Major Shareholding Notification
2019-05-10 English
OXUR transparency statement OXUR aandelen 100519 NL.pdf
Share Issue/Capital Change
2019-05-10 Dutch
PR_OXUR BU Q1 080519.pdf
Management Reports Q1 2019
2019-05-08 English
OXUR 2ndEGM 24MAY2019 Proxy (Dutch&English).pdf
Proxy Solicitation & Information Statement
2019-05-07 Dutch
OXUR 2nd EGM 24MAY2019 ConveningNotice (Dutch&English).pdf
AGM Information
2019-05-07 Dutch
OXUR Proposed Amendments Articles Of Association.PDF
Regulatory Filings
2019-04-04 Dutch
OXUR AGM_EGM 07MAY19 Volmacht_Proxy (Dutch&English).pdf
AGM Information
2019-04-04 Dutch
OXUR AGM_EGM 07MAY19 ShareholderRights (Dutch&English).pdf
AGM Information
2019-04-04 Dutch
OXUR AGM_EGM 07MAY19 ConveningNotice (English).pdf
AGM Information
2019-04-04 English
OXUR AGM_EGM 07MAY19 ConveningNotice (Dutch).pdf
AGM Information
2019-04-04 Dutch
Annual Report - financial information 2018.pdf
Annual Report FY 2018
2019-04-04 English
Jaarverslag - financiële informatie 2018.pdf
Annual Report FY 2018
2019-04-04 Dutch
OXUR BU FY18 070319 EN FIN.pdf
Management Reports FY 2018
2019-03-07 English
OXUR BU FY18 070319_NL FIN.pdf
Audit Report / Information FY 2018
2019-03-07 Dutch